HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. - Wikidata - wikimedia - TriplyDB

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

http://www.wikidata.org/entity/Q37340316

about

Human CD4(+) T-Cells: A Role for Low-Affinity Fc Receptors Clinical use and applications of histone deacetylase inhibitors in multiple myeloma HDAC inhibitors and immunotherapy; a double edged sword?Regulatory myeloid cells in transplantation Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages The role of epigenetic mechanisms and processes in autoimmune disorders Dendritic cell-associated miRNAs are modulated via chromatin remodeling in response to different environments.Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4 Histone/protein deacetylases and T-cell immune responses Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.Enhanced B Cell Alloantigen Presentation and Its Epigenetic Dysregulation in Liver Transplant Rejection HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.Histone deacetylase inhibitors in the generation of the anti-tumour immune response.HDACi: molecular mechanisms and therapeutic implications in the innate immune system.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.The therapeutic potential of epigenetics in autoimmune diseases.Panobinostat for the treatment of multiple myeloma.Transcriptional and epigenetic networks in the development and maturation of dendritic cells.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.Novel therapies for cutaneous T-cell lymphoma: what does the future hold?Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Epigenomics of autoimmune diseases.Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships.Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma Epigenetics and innate immunity: the 'unTolld' story.Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands.Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients.Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.Modulation of antitumor immunity with histone deacetylase inhibitors.

P2860

Q26745538-A03E55C8-0959-4510-9D5B-7EC1D6456693 Q26745930-CC33C8ED-8868-405E-A49F-FCEFA22028A7 Q26853102-8ED21612-CB68-4557-AAF8-577F19EE95E7 Q26999875-C1255175-3E02-4372-9E5C-03B9AD73B389 Q28294510-103E9214-F8D6-473F-90ED-9F03AC8CE649 Q28389137-25B5B0A1-3DF2-4D20-BA0A-A12CAF5C8B1D Q31155451-7D5E21C0-86BF-4DE5-8B75-BB359116CB7D Q32945672-1BF6479E-2536-4066-A08D-626A601641EC Q33570005-67EC9335-C23F-42B5-AE86-69FD2D826909 Q33928765-C9A076C3-3B37-4A6A-8244-0C0611406AB2 Q34935239-380A656C-AD0D-4AC8-85D5-398FBC40561C Q35016934-AEEF5691-43DE-45B2-B4BE-EF8DEA3C70DD Q35556061-4A634DAB-B1C2-4FD1-B41F-4BE64318DB73 Q35849307-5ACCE11B-21C1-4F9E-9C5D-97A0991DC47E Q36799721-AAE45200-5C32-421B-8B4A-0A807481C840 Q36802272-7A404417-A914-4892-8C84-B55C1D2BE880 Q37340304-45ADDD7E-54C9-458D-8F41-EE6EA6A6AF8D Q37370835-6F359E53-D029-4709-8C1E-E05C6EE6AF4C Q37949185-43C82F83-7559-431D-9AAE-4FF2608A992D Q37953826-14D94D91-2BDA-486A-B5D8-D2F1BE4C1A1C Q37956176-24791C3E-1211-4B55-9F28-07DFDABA29CE Q37959304-87B7121E-A19A-4FD3-ADB6-CE1D41749DC5 Q37967566-A2D6220D-0127-4E40-BFD7-72CE387BE6ED Q37992104-9DED28E8-F7CA-4CC9-9E11-A5E9890C09F2 Q38097109-2224C1A8-8326-42DF-AA64-495D485CF8DA Q38110935-6C21A63B-9B9E-442F-B45F-68221A367DD3 Q38159805-6AA4B564-A1DA-4026-8C06-01795BDB0E9C Q38176398-BF1A00DF-556C-4192-95DB-29F9E4CFE8E7 Q38240733-84A78027-FF96-4445-8739-20E3D62753D5 Q38380209-2DBD7F8B-8A2A-4802-BBBE-64BF8E3947ED Q38530238-50B06163-28BE-41DB-8943-73D1B7FDCA17 Q38740003-C993DE8C-52E5-425D-9AB3-2EB1E0E00A05 Q38754198-87788872-256D-4165-9A4E-1EFA2ED898E2 Q38763747-A66649FD-C709-49C6-8ACE-7F24C7167019 Q38950582-A64264D1-4436-4FEA-8B36-8140753CC93B Q39323511-EC9579FA-99FE-469C-8D64-01ED61E2F5A8 Q41885967-435CE34C-A1CD-403B-9F1D-1C066D7C1EEE Q43497561-EB4F6AB0-307D-4B7F-8EB3-50D3F5B77A3F Q47793104-9798C576-9446-4028-A719-D69B3C05CF38 Q49557954-4882BC30-253D-4F62-9DB9-A7866926A2B8

P2860

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

http://www.wikidata.org/entity/Q37340316

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.

@en

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.

@nl

type

label

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.

@en

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.

@nl

prefLabel

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.

@en

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells.

@nl

P1433

Q37340316-3D61FCE3-9862-43EA-B211-9920F71A7F38

P1476

Q37340316-E07F6EC4-A350-448F-A680-472BEF120415

P2093

Q37340316-28311709-6FCB-4A39-A949-6FC61350A539

Q37340316-381CC09D-A01B-4928-810A-D17CB5BEB286

Q37340316-3FA522F1-2369-4A79-AA1D-A87045AE43CA

Q37340316-5E163A9A-C253-4710-BFD9-BFA8CAAB12AA

Q37340316-CF11F5C6-88D0-4B38-833F-4FDBAE8CBFE9

Q37340316-DAFE62AA-1A8B-4258-8E8C-5699DE0DCDF6

Q37340316-F3879F07-0870-48CB-ACFA-ADD178BF0E20

Q37340316-F5930DA8-6D0D-4320-B074-9BF4405037C2

P2860

Q37340316-0E022D6F-9DDB-48E6-BC6F-8B1592513F3C

Q37340316-1513526A-FFA7-4F48-AB55-B41BDE9F2C1E

Q37340316-19026CE3-0024-4930-B5E4-C4E8669B87BF

Q37340316-1BB0A58F-3A30-412E-B35E-9BE6EC1B0D64

Q37340316-1D2D14E7-77F9-4CC3-947A-05C97E4D9100

Q37340316-45BC23F5-4FCF-4E2B-B026-5FEDEABF4996

Q37340316-49F6653F-3D17-4A56-A63F-DBBD4793B895

Q37340316-4D7F4816-DFEE-4358-8AD6-567D4E727F9C

Q37340316-5D093ABA-6493-42FA-9EF3-DECCBA576C9A

Q37340316-6959037D-B079-4A48-9143-3C92C65303F8

P2888

Q37340316-EFDE39AA-4259-44DB-9A0B-75E094A3922B

P304

Q37340316-1B8FFA4E-75C8-4D6C-84F0-CDC5CFEB5493

P31

Q37340316-FBF86B0F-3C6C-4C70-A63C-7059FE9C0D96

P356

Q37340316-63D3E485-5DDC-458B-922B-644E2EE013CC

P433

Q37340316-4CBA1F44-E398-4C5D-9651-23B40407CEC3

P478

Q37340316-81B62D82-9F10-4C67-BC04-B76DEE567306

P50

Q37340316-E114CAD0-327B-428F-AE49-D015E49C0168

P577

Q37340316-DED5FCD7-4EEC-4DA8-AB93-FB2D074EF086

P5875

Q37340316-A6B19F9E-7C35-4FD9-BAF1-D024BD155732

P698

Q37340316-4B152124-068A-4120-81B4-4B0982239CB9

P932

Q37340316-739B3D39-535E-474B-B3F7-0880506CCEE2

P356

P1433

P1476

HDAC inhibition by LBH589 affe ...... human myeloid dendritic cells

@en

P2093

D Chauhan

http://www.w3.org/2001/XMLSchema#string

K C Anderson

http://www.w3.org/2001/XMLSchema#string

N C Munshi

http://www.w3.org/2001/XMLSchema#string

P Nanjappa

http://www.w3.org/2001/XMLSchema#string

T Hideshima

http://www.w3.org/2001/XMLSchema#string

W Song

http://www.w3.org/2001/XMLSchema#string

Y-T Tai

http://www.w3.org/2001/XMLSchema#string

Z Tian

http://www.w3.org/2001/XMLSchema#string

P2860

Antigen presentation and T cell stimulation by dendritic cells

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice

Pathogen recognition and innate immunity

Histone deacetylases and cancer

Clinical development of histone deacetylase inhibitors as anticancer agents

IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Going both ways: immune regulation via CD1d-dependent NKT cells.

P2888

P304

161-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2010.244

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49630978

http://www.w3.org/2001/XMLSchema#string

P698

21102427

http://www.w3.org/2001/XMLSchema#string

P932

3839585

http://www.w3.org/2001/XMLSchema#string